Productivity burden of smoking in Australia: a life table modelling study.


Journal

Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612

Informations de publication

Date de publication:
05 2019
Historique:
received: 18 01 2018
revised: 04 06 2018
accepted: 06 06 2018
pubmed: 18 7 2018
medline: 11 1 2020
entrez: 18 7 2018
Statut: ppublish

Résumé

This study aimed to examine the impact of smoking on productivity in Australia, in terms of years of life lost, quality-adjusted life years (QALYs) lost and the novel measure of productivity-adjusted life years (PALYs) lost. Life table modelling using contemporary Australian data simulated follow-up of current smokers aged 20-69 years until age 70 years. Excess mortality, health-related quality of life decrements and relative reduction in productivity attributable to smoking were sourced from published data. The gross domestic product (GDP) per equivalent full-time (EFT) worker in Australia in 2016 was used to estimate the cost of productivity loss attributable to smoking at a population level. At present, approximately 2.5 million Australians (17.4%) aged between 20 and 69 years are smokers. Assuming follow-up of this population until the age of 70 years, more than 3.1 million years of life would be lost to smoking, as well as 6.0 million QALYs and 2.5 million PALYs. This equates to 4.2% of years of life, 9.4% QALYs and 6.0% PALYs lost among Australian working-age smokers. At an individual level, this is equivalent to 1.2 years of life, 2.4 QALYs and 1.0 PALY lost per smoker. Assuming (conservatively) that each PALY in Australia is equivalent to $A157 000 (GDP per EFT worker in 2016), the economic impact of lost productivity would amount to $A388 billion. This study highlights the potential health and productivity gains that may be achieved from further tobacco control measures in Australia via application of PALYs, which are a novel, and readily estimable, measure of the impact of health and health risk factors on work productivity.

Identifiants

pubmed: 30012640
pii: tobaccocontrol-2018-054263
doi: 10.1136/tobaccocontrol-2018-054263
pmc: PMC6580760
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

297-304

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Tob Use Insights. 2015 Jul 14;8:1-35
pubmed: 26242225
BMC Public Health. 2016 Jan 26;16:77
pubmed: 26813029
J Med Econ. 2017 Sep;20(9):938-944
pubmed: 28685629
Ann Intern Med. 2006 Mar 21;144(6):381-9
pubmed: 16549850
Br Med Bull. 2012;101:17-31
pubmed: 22331197
Value Health. 2016 Jul-Aug;19(5):558-66
pubmed: 27565273
Diabetes Care. 2018 May;41(5):979-984
pubmed: 29490901
Br Med Bull. 2010;96:5-21
pubmed: 21037243
BMC Med. 2015 Feb 24;13:38
pubmed: 25857449
Int J Clin Pract. 2017 Jan;71(1):
pubmed: 28097760
Tob Control. 2016 Sep;25(5):532-7
pubmed: 26427527
Lancet. 2017 Mar 25;389(10075):1229-1237
pubmed: 28159391
Am J Prev Med. 2010 Feb;38(2):138-44
pubmed: 20117569
J Occup Environ Med. 2006 Oct;48(10):1099-108
pubmed: 17033509
Tob Control. 2008 Dec;17(6):379-84
pubmed: 18719075
JAMA. 2014 Jan 8;311(2):183-92
pubmed: 24399557
Prev Med. 2005 Jul;41(1):276-83
pubmed: 15917022
BMC Public Health. 2016 Jul 27;16:646
pubmed: 27460828
BMJ. 2004 Jun 26;328(7455):1519
pubmed: 15213107
Eur J Public Health. 2002 Jun;12(2):145-51
pubmed: 12073754
Lancet. 2015 Dec 5;386(10010):2287-323
pubmed: 26364544
Addiction. 2013 Feb;108(2):307-19
pubmed: 23078132
Tob Control. 2010 Feb;19(1):7-12
pubmed: 19748886
Med Care. 2005 Nov;43(11):1078-86
pubmed: 16224300
Tob Control. 2018 Jan;27(1):58-64
pubmed: 28138063

Auteurs

Alice J Owen (AJ)

Centre for Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash Univeristy, Melbourne, Victoria, Australia.

Salsabil B Maulida (SB)

Centre for Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash Univeristy, Melbourne, Victoria, Australia.
Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.

Ella Zomer (E)

Centre for Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash Univeristy, Melbourne, Victoria, Australia.

Danny Liew (D)

Centre for Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash Univeristy, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH